AGA GUIDELINES Bundle (free trial)

Adult Obesity

AGA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512444

Contents of this Issue

Navigation

Page 7 of 9

Table 1. Anti-obesity Medications Agent Brand name Dose Contraindications a Diethylpropion Generic 25 mg tid PO one hour before meals; 75 mg sustained- release tab PO mid- morning Pulmonary hypertension, advanced arteriosclerosis, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma, severe hypertension Gelesis100 oral superabsorbent hydrogel Plenity ree with water before meals Risk factors for bowel obstruction Liraglutide Saxenda 3 mg daily subcutaneous (subcut) Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Naltrexone- bupropion ER Contrave 32 mg/180 mg bid Seizure disorder, opiate therapy, monoamine oxidase inhibitors (MAOIs), severe renal or hepatic disease. Caution advised in patients at high risk of seizures Phentermine Generic Adipex, Suprenza, Lomaira 4–8 mg tid; 15–37.5 mg qAM Cardiovascular disease, MAOIs, hyperthyroidism, history of drug abuse, uncontrolled hyperension Phentermine- topiramate ER Generic Qsymia 7.5 mg/46 mg qAM or 15 mg/92 mg qAM Phentermine: Cardiovascular disease, MAOIs, hyperthyroidism, history of drug abuse, uncontrolled hyperension Topiramate: Associated with an increassed risk of teratogenicity, specifically oral cles Semaglutide Wegovy 2.4 mg subcut weekly Personal or family history of MTC or in patients with MEN 2 a All AOMs should be avoided during pregnancy and nursing.

Articles in this issue

Archives of this issue

view archives of AGA GUIDELINES Bundle (free trial) - Adult Obesity